Steven E. Finkelstein, MD, FACRO, presented “New Approaches to Combining Brachytherapy with Immunotherapy” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Finkelstein, Steven E. “New Approaches to Combining Brachytherapy with Immunotherapy” January 23rd, 2020. Accessed Nov 2024. https://grandroundsinurology.com/new-approaches-to-combining-brachytherapy-with-immunotherapy/
New Approaches to Combining Brachytherapy with Immunotherapy – Summary:
Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses the growing field of brachytherapy-driven immunotherapy and its potential role in prostate cancer treatment. He goes on to discuss the mechanisms behind radiation-induced tumor death, the growing evidence behind the immunostimulatory effects of radiation, and a patent describing a radiation-based applicator and potential method for administering immunotherapy agents to cancerous tissue.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Finkelstein gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Steven E. Finkelstein, MD, FACRO, is the Director of the Center of Advanced Radiation Excellence, and Director of Radiation Oncology Research for Associated Medical Professionals in Syracuse, New York. His interests include the research of a variety of cancers, busting radiation driven, and personalized systemic therapy. He holds three international patents in the field of cutting edge technologies.
Dr. Finkelstein received his medical degree from the University of Michigan Medical School, graduating cum laude eruditions causa. He then joined the National Cancer Institute, National Institutes of Health as Clinical Associate. He completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship, and an additional radiation oncology residency.
He served a residency in General Surgery at Washington University in Saint Louis, Missouri, Dr. Finkelstein also served fellowships in Biologic Immunotherapy, Clinical Cancer, and Surgical Oncology at the Surgery Branch of the National Cancer Institute in Bethesda, Maryland. He is a member of the American College of Radiation Oncology, the American Medical Association, the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, the Radiological Society of North America, and the Radiation Therapy Oncology Group.
He has served as a Co-Chair on the NRG Immunotherapy Committee, Co-Chair of the 2018-2019 ACRO Scientific Program Committee, and Chair of the SWOG Radiation STG Committee. He currently serves on the Board of Chancellors for ACRO. Dr. Finkelstein has also served as National Director of Translational Research Consortium (TRC), the cutting-edge therapy arm of 21st Century Oncology in Scottsdale, Arizona. Inspired by his grandmother, a cancer patient, he became a dedicated cancer surgeon who found that radiation therapy could sometimes do for his patients what surgery could not.
